. y6 b* {6 ?7 j; o4 W临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究: 2 Y2 Y2 }# A l( [ w ~! [Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer. `5 M, f- e! i& M) Ghttp://www.ncbi.nlm.nih.gov/pubmed/22968184$ z7 C8 s. R. }5 W n$ c `% ]
$ f. t. g9 }- A
依维莫司联合吉非替尼抑制非小细胞肺癌细胞系的效果和作用机制" ~9 k8 V& x ~ http://d.wanfangdata.com.cn/Thesis_Y1770447.aspx